[-] Show simple item record

dc.contributor.authorDickerson, Lori M.eng
dc.contributor.authorYoung, Sara E.eng
dc.contributor.authorSimpson, William M.eng
dc.contributor.authorNashelsky, Joaneng
dc.date.issued2005eng
dc.description.abstractTreatment of early Parkinson's disease with either selegiline (Eldepryl), a dopamine agonist (pramipexole [Mirapex], ropinirole [Requip], or bromocriptine [Parlodel]), or the combination of levodopa and carbidopa (Sinemet) or levodopa and cabidopa with entacapone (Stalevo) improves symptoms and quality of life, but all medication regimens are associated with significant side effects (Table 1). There is no compelling evidence favoring a medication option, so treatment should be individualized. [Strength of recommendation: A, based on systematic reviews of randomized controlled trials (RCTs)]eng
dc.identifier.urihttp://hdl.handle.net/10355/3961eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2005 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesAmerican family physician, 72, no. 03 (August 2005)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectcogwheel rigidityeng
dc.subjectresting tremoreng
dc.subjectbradykinesiaeng
dc.subjectcombination therapyeng
dc.subject.lcshParkinson's disease -- treatmenteng
dc.subject.lcshAntiparkinsonian agentseng
dc.subject.lcshSelegilineeng
dc.subject.lcshParkinson's disease -- Chemotherapyeng
dc.titleTreatment of Early Parkinson's Diseaseeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record